A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography
This multicenter study aims to establish the normal reference range of the Right Atrioventricular Coupling Index (RACI) in healthy Chinese adults using AI-based 3DE technology. It will also analyze the correlation between RACI and physiological parameters such as age, gender, and body surface area. Additionally, the study will explore the variation characteristics of RACI in patients with pulmonary hypertension, heart failure, tricuspid regurgitation, and atrial septal defect, and evaluate the clinical value of RACI in disease diagnosis, differential diagnosis, and risk stratification.
Eligibility
Sex
ALL
Min age
18 Years
Max age
79 Years
Healthy volunteers
Accepted
Healthy Adults Group
Inclusion Criteria:
* Participants must meet all of the following criteria to be enrolled:
1. Of Han Chinese ethnicity
2. Aged 18-79 years
3. Normal blood pressure (\< 140/90 mmHg)
4. Normal fasting blood glucose
5. Normal blood lipid levels (triglycerides, total cholesterol, low-density lipoprotein, high-density lipoprotein)
6. Normal complete blood count results (hemoglobin concentration, white blood cell count, red blood cell count, platelet count)
7. Normal liver and renal function (alanine transaminase \< 2× upper limit of normal; normal creatinine and blood urea nitrogen)
8. Normal electrocardiogram results (occasional atrial premature beats may be enrolled at the investigator's discretion)
9. No structural heart disease and normal cardiac function confirmed by echocardiography
Exclusion Criteria:
Participants will be excluded if they meet any of the following criteria:
1. Clinically significant cardiac valve regurgitation (≥ mild severity)
2. Respiratory diseases: acute or chronic respiratory disorders
3. Endocrine diseases: thyroid disease, diabetes mellitus, hyperaldosteronism, pheochromocytoma, etc.
4. Abnormal liver function (alanine transaminase \> 2× upper limit of normal), abnormal renal function (elevated creatinine beyond normal range), or dyslipidemia (elevated triglycerides, total cholesterol, low-density lipoprotein, or high-density lipoprotein)
5. Other systemic diseases: anemia, malignancy, connective tissue disease, large artery/peripheral vascular diseases (aortic dilation, aortic dissection, coarctation of the aorta, Takayasu arteritis, atherosclerosis), etc.
6. Pregnant or lactating women
7. Professional athletes
8. Poor-quality ultrasound images that cannot support parameter measurement and analysis
Pulmonary Hypertension Group
Inclusion Criteria:
Patients must meet all of the following criteria to be enrolled:
1. Aged 18-79 years
2. Confirmed diagnosis via right heart catheterization: mean pulmonary arterial pressure (mPAP) ≥ 20 mmHg, in accordance with the 2022 ESC/ERS guidelines
Exclusion Criteria:
Patients will be excluded if they meet any of the following criteria:
1. Unable to complete right heart catheterization or pressure-volume loop assessment
2. Complicated with significant left heart disease (left ventricular ejection fraction \[LVEF\] \< 50%, significant mitral valve disease)
3. Pericardial disease or arrhythmias (e.g., atrial fibrillation) that severely impair right heart function evaluation
4. Poor-quality images that prevent accurate measurement of right atrial or right ventricular parameters
5. Concurrent liver or renal disease
6. Concurrent malignancy
7. History of surgical procedures such as pulmonary endarterectomy or balloon pulmonary angioplasty
Heart Failure Group
Inclusion Criteria:
Patients must meet all of the following criteria to be enrolled:
1. Aged 18-79 years
2. Meets the 2022 AHA/ACC/HFSA diagnostic criteria for heart failure
Exclusion Criteria:
Patients will be excluded if they meet any of the following criteria:
1.Complicated with significant valvular heart disease (e.g., severe mitral regurgitation, severe tricuspid regurgitation, etc.)
Tricuspid Regurgitation Group
Inclusion Criteria:
Patients must meet all of the following criteria to be enrolled:
1. Moderate or severe primary or secondary tricuspid regurgitation confirmed by echocardiography
2. Aged 18-79 years
Exclusion Criteria:
Patients will be excluded if they meet any of the following criteria:
1. Pericardial disease or arrhythmias (persistent atrial fibrillation) that interfere with measurements
2. Congenital heart disease or residual lesions after surgical correction
Atrial Septal Defect Group
Inclusion Criteria:
Patients must meet all of the following criteria to be enrolled:
1. Secundum atrial septal defect confirmed by echocardiography or transesophageal echocardiography
2. Patients who have not undergone closure or surgical correction, or stable patients with \> 3 months postoperatively
3. Aged 18-79 years
Exclusion Criteria:
1.Complicated with other complex congenital heart diseases.
Primary outcome measure(s)
Right Atrioventricular Coupling Index (RACI) — At study enrollment (baseline) RACI links the volumes of the right atrium (RA) and right ventricle (RV), with the degree of their volume matching reflecting their synergistic functional status during hemodynamic regulation
Trial sites (25)
Facility
City
Region
Status
Chongqing Liangjiang New Area Hospital of Traditional Chinese Medicine
Chongqing
Chongqing Municipality
Shenzhen People's Hospital
Shenzhen
Guangdong
Shijiazhuang People's Hospital
Shijiazhuang
Hebei
The Third Affiliated Hospital of Hebei Medical University
Shijiazhuang
Hebei
The First Affiliated Hospital of Harbin Medical University
Harbin
Heilongjiang
The Fourth Affiliated Hospital of Harbin Medical University
Harbin
Heilongjiang
Henan Provincial People's Hospital
Zhengzhou
Henan
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan
Hubei
Xiangyang No.1 Peoples Hospital
Xiangyang
Hubei
The Second Affiliated Hospital of Jilin University
Changchun
Jilin
Anshan Central Hospital
Anshan
Liaoning
Ansteel Group General Hospita
Anshan
Liaoning
Chaoyang Central Hospital
Chaoyang
Liaoning
the Second Hospital of Dalian Medical University
Dalian
Liaoning
Huludao Second People's Hospital
Huludao
Liaoning
Liaohua Hospital
Liaoyang
Liaoning
The First Hospital of China Medical University
Shenyang
Liaoning
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an
Shaanxi
The Second Affiliated Hospital of Shaanxi University of Chinese Medicine
Xianyang
Shaanxi
The Affiliated Hospital of Qingdao University
Qingdao
Shandong
Shanxi Provincial People's Hospital
Taiyuan
Shanxi
West China Hospital,Sichuan University
Chengdu
Sichuan
Beijing Chaoyang Hospital, Capital Medical University
Beijing
China
Shanghai Chest Hospital
Shanghai
China
Zhongshan Hospital, Fudan University, Shanghai
Shanghai
China
More First Hospital of China Medical University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.